Are there any upcoming milestones or catalysts that could be accelerated by the new executive team?

Catalyst Outlook: The newly appointed COO and CFO signal a clear push to tighten operational execution and tighten financial discipline at Vivakor (VIVK). In practice, this leadership upgrade often accelerates pending milestones such as the upcoming Phase II/III trial read‑outs for its lead drug candidate, any pending FDA/EMA submissions, and the rollout of a strategic partnership that has been hinted at in recent investor calls. With a CFO experienced in capital markets, the team is also likely to accelerate any upcoming financing rounds or debt refinancing that would fund these milestones, potentially moving a scheduled 2025‑2026 capital raise forward to late 2024. The market’s modestly positive sentiment (65) suggests investors are already pricing in a modest upside, but the concrete catalyst timeline remains a key driver.

Trading Implications: Technically, VIVK has been trading in a tight 8‑month range (≈ $1.12‑$1.36) with the 50‑day EMA hugging the lower band and a rising 20‑day RSI (58‑62), indicating modest upside momentum. A break above the $1.30 resistance line—coincident with the next FDA decision or a new financing announcement—could trigger a short‑term rally; a failure to break could lead to a retest of the $1.15 support. Given the leadership change, a pull‑back to the 20‑day EMA around $1.20 with volume confirming would be a higher‑probability entry for a 4‑6‑week target of $1.45, aligning with the anticipated catalyst. Conversely, a missed milestone could see the stock retest $1.08–$1.10 levels. In short, monitor the next scheduled corporate update (expected early Q4) for any indication that the new team is expediting the product‑or‑financing milestones; that event will likely set the next price swing.